№ lp_2_3_66464
File format: docx
Character count: 16804
File size: 35 KB
This is a combined synopsis/solicitation for the procurement of a Breast Biopsy System for the Department of Veterans Affairs, Miami, including detailed specifications and requirements for interested small businesses.
Year:
2017
Region / City:
Miami, Florida
Subject:
Procurement of Medical Equipment
Document Type:
Combined Synopsis/Solicitation
Agency:
Department of Veterans Affairs
Author:
Department of Veterans Affairs
Target Audience:
Service Disabled/Veteran Owned Small Businesses
Period of Effectiveness:
From January 19, 2017
Approval Date:
January 19, 2017
Modification Date:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology
Note:
Year
Theme:
Neuropathology, Biopsy, Medical Guidelines
Document Type:
Guidelines
Organization / Institution:
Southmead Hospital
Target Audience:
Medical professionals, Neuropathologists
Context:
Guidelines for handling and sending nerve biopsy specimens to the Neuropathology Department for analysis and further processing.
Note:
Year
Subject:
Neuropathology, Prion Diseases
Document Type:
Procedure
Organization / Institution:
National Prion Disease Pathology Surveillance Center
Author:
Chad Patete for Dr. Gambetti
Target Audience:
Neuropathologists, Medical Staff
Version:
4.2.0.0
Protocol Posting Date:
June 2024
Year:
2024
Region / city:
Not specified
Topic:
Bone tumor biopsy protocols
Document type:
Protocol
Organization / institution:
Not specified
Author:
Paari Murugan, MD, FCAP; Julie C. Fanburg-Smith, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD
Target audience:
Clinicians and pathologists involved in biopsy procedures for bone tumors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Year
Topic:
Medical Procedure
Document Type:
Educational Material and Consent Form
Target Audience:
Patients undergoing vulvar biopsy
Contextual description:
Document providing detailed information and consent form for patients undergoing vulvar biopsy, including risks, procedure details, and alternatives.
Subject:
Lung cancer diagnosis and procedure coding
Diagnosis codes:
ICD-9 162.0, 162.2, 162.3, 162.4, 162.5, 162.8, 162.9; ICD-10 C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92
Procedure codes:
CPT, ICD-9 Procedure, ICD-10 Procedure
Clinical focus:
Biopsy procedures, CT scans, treatments, and post-procedural complications
Complication types:
Pneumothorax, prolonged air leak, hemorrhage, intubation/mechanical ventilation, mediastinitis, pneumonia, empyema, abscess of lung
Setting:
Inpatient and outpatient hospital care
Cost attribution rule:
Inpatient biopsies after day 2 costed at outpatient rate
Purpose:
Patient selection and identification of post-procedural complications and treatments
Coding systems referenced:
ICD-9-CM, ICD-10-CM, CPT
Version:
1
Date:
June 2014
Authors:
Annie Kao; Bryony Aldous
Approver:
Mary Glover
Document type:
Clinical competency workbook
Subject:
Punch skin biopsy training and assessment
Target audience:
Registered children’s nurses (Band 6 or above)
Purpose:
Assessment of theoretical knowledge and practical competence in punch skin biopsy
Assessment requirements:
Completion of workbook; observation of two procedures; supervised performance of four procedures; competency sign-off
Related policies:
Medication Administration Policy (2012); Consent Policy (2013); Patient Group Directions Policy (2013); Hand Hygiene (2014); Disposal of Used Sharps (2014); Management of Severe Local Anaesthetic Toxicity (2010)
Procedure scope:
Punch skin biopsy only
Clinical setting:
Trust clinical practice
Year:
Not specified
Region / City:
Not specified
Topic:
Medical procedure, prostate biopsy
Document Type:
Consent form
Author:
Not specified
Target Audience:
Patients undergoing prostate biopsy
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Context:
A medical consent form outlining the risks, benefits, and procedure of transrectal ultrasound and prostate biopsy.
Year:
2020
Region / city:
Australia
Subject:
Health / Medical Services
Document type:
Factsheet
Organization / institution:
Medicare
Author:
MBS Review Taskforce
Target audience:
Healthcare providers, patients, medical professionals
Effective period:
From 1 May 2020
Approval date:
16 April 2020
Modification date:
N/A
Sample size:
10378 patients
Medical condition:
Prostate cancer
Subgroups:
Clinically significant prostate cancer (csPCa), Insignificant prostate cancer (Ins-PCa), All prostate cancer (PCa)
Variables analyzed:
Age, PSA level, Prostate volume (PV), PSA density (PSAD), PI-RADS score
Age categories:
<50; 50–60; 60–70; 70–80; ≥80 years
PSA categories:
<10; 10–20; 20–50; 50–100; ≥100 ng/mL; Unknown
Prostate volume categories:
<30; 30–40; 40–60; ≥60 ml; Unknown
PSA density categories:
<0.1; 0.1–0.15; 0.15–0.2; ≥0.2; Unknown
Imaging classification system:
PI-RADS (Prostate Imaging-Reporting and Data System)
Data type:
Quantitative clinical characteristics with counts and percentages
Medical field:
Urology / Oncology
Document type:
Statistical table of clinical study data
Version:
4.1.0.0
Protocol Posting Date:
December 2022
Recommended Use:
Clinical care purposes
Not Required For Accreditation:
Yes
Procedures Covered:
Biopsy (core, incisional, other)
Tumor Types Covered:
Pediatric hepatoblastoma
Excluded Procedures:
Resection
Excluded Tumor Types:
Other primary malignant hepatic tumors
Authors:
Jessica L. Davis, MD; Soo-Jin Cho, MD, PhD; Grace Kim, MD; Sarangarajan Ranganathan, MD; Delores Lopez-Terrada, MD, PhD; Allison F. O’Neal, MD; Arun Rangaswami, MD
Guidance Committees:
CAP Cancer and CAP Pathology Electronic Reporting Committees
Core Data Elements:
Routinely reported
Non-Core Data Elements:
Indicated with +
Updates:
WHO 5th edition, Expert Consultation updated from Conditional to Optional
Target Audience:
Pathologists, oncologists, clinical researchers
Document Type:
Clinical protocol / case summary
Year:
2025
Region / City:
United States
Subject:
Pediatric Rhabdomyosarcoma Biopsy Procedures
Document Type:
Clinical Protocol
Organization:
College of American Pathologists (CAP)
Authors:
Jessica L. Davis, MD; Erin Rudzinski, MD; Michael Arnold, MD, PhD; Archana Shenoy, MD; Lea Surrey, MD; Aaron Weiss, DO
Target Audience:
Pathologists, Laboratory Staff
Effective Period:
June 2024 – present
Version:
5.0.0.1
Accreditation Requirements:
CAP Laboratory Accreditation Program
Procedures Covered:
Core biopsy, incisional biopsy, excisional biopsy
Tumor Types Covered:
Pediatric rhabdomyosarcoma and ectomesenchymoma variants
Excluded Procedures:
Adult rhabdomyosarcoma, tumor resections
Reporting Format:
Synoptic report with core and conditional data elements
Glossary:
Defines roles of authors and expert contributors
Contact:
[email protected]
Year:
2025
Region / City:
North West NHS GMS region
Topic:
ctDNA testing for NSCLC and breast cancer
Document Type:
Notification
Organization:
NHS England
Author:
Genomics Unit
Target Audience:
NHS Trusts
Period of Action:
2025/26 financial year
Approval Date:
7 November 2025
Date of Changes:
N/A
Context:
Notification regarding the continuation and expansion of ctDNA testing for lung and breast cancer in the North West NHS region for the 2025/26 financial year.
Year:
2024
Region / City:
International
Subject:
Nuclear medicine, breast cancer, estrogen receptor imaging
Document type:
Procedure standard / Practice guideline
Organization:
SNMMI, EANM
Authors:
David Mankoff, Sona Balogova, Lisa Dunnwald, Farrokh Dehdashti, Erik DeVries, Laura Evangelista, Michel Van Krutchen, Sofia Carriho Vaz, Amy Fowler, Hannah Linden, Gary Ulaner
Target audience:
Nuclear medicine practitioners, oncologists
Scope period:
Current clinical practice
Approval date:
2024
Revision cycle:
Every 5 years or sooner if indicated
Description:
Clinical guideline detailing standardized procedures for [18F]FES PET imaging of estrogen receptor expression in breast cancer patients, including methodology, interpretation, and quality assurance for diagnostic nuclear medicine.
Version:
4.4.0.0
Protocol Posting Date:
June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2022
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Note:
Accreditation Requirements
Year:
2021
Region / City:
Global
Theme:
Oncology, Breast Cancer
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Medical professionals, pathologists
Period of Validity:
From March 2022
Date of Approval:
June 2021
Date of Changes:
June 2021
Year:
2024
Region / City:
Not specified
Subject:
Pathology, Oncology
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Uma G. Krishnamurti, MD, PhD; Kimberly H. Allison, MD; Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Pathologists, Medical Institutions
Period of Validity:
March 2025
Approval Date:
Not specified
Date of Last Change:
June 2024
Version:
1.2.0.0
Protocol posting date:
March 2023
Document type:
Clinical pathology protocol
Medical field:
Breast pathology, oncology
Procedures covered:
Needle biopsy, fine needle aspiration, other biopsy procedures
Tumor types included:
Invasive breast carcinoma of any type, with or without ductal carcinoma in situ
Tumor types excluded:
Ductal carcinoma in situ without invasion, Paget disease without invasion, phyllodes tumor, lymphoma, sarcoma
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Organization:
College of American Pathologists
Accreditation status:
Recommended for clinical care, not required for accreditation
Intended use:
Reporting of biopsy specimens
Updates:
Optional reporting of largest invasive focus; revised lymphatic and/or vascular invasion terminology